Related Experiment Video
Updated: Jun 5, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
188
Clinical Manifestations of Semaglutide Overdose: A Case Study
Matthew R Branch1, Isabella E Amador, Irina Tardif
1Department of Psychiatry, University of Florida College of Medicine, Jacksonville, Jacksonville, FL.
Journal of Psychiatric Practice
|December 10, 2024
Summary
Intentional overdose of semaglutide (Ozempic) resulted in mild, self-limiting symptoms. This case study highlights the favorable safety profile of Ozempic, a popular medication for diabetes and weight loss.
Area of Science:
- Endocrinology
- Clinical Pharmacology
- Toxicology
Background:
- Semaglutide (Ozempic) is a widely prescribed glucagon-like peptide-1 receptor agonist for type 2 diabetes and weight management.
- Intentional overdose cases are rare, necessitating further understanding of its safety in supratherapeutic doses.
Observation:
- A case report details a 39-year-old transgender female-to-male patient who intentionally overdosed on semaglutide.
- The patient presented with mild, self-limiting symptoms following the overdose.
Findings:
- The overdose did not lead to severe adverse events, indicating a potentially wide safety margin for semaglutide.
- Symptoms experienced were transient and manageable without significant medical intervention.
Implications:
- This case suggests that semaglutide possesses a favorable safety profile, even in cases of intentional overdose.
- Findings support the continued use of semaglutide for its approved indications, reinforcing its therapeutic safety in clinical practice.
Related Concept Videos
01:15Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:15Diabetes: Symptoms, Diagnosis, and Complications
504
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
504
01:14Prevention of Further Absorption of Poison
782
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
782
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
01:16Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145